2026 ICD-10-CM Diagnosis Code E04.2Nontoxic multinodular goiter
ICD-10-CM Codes›E00–E89›E00-E07›E04
- Billable — Valid for Submission
- Chronic Condition
E04.2 is a billable ICD-10-CM diagnosis code for nontoxic multinodular goiter. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 643 through 645. Coders also document this condition as autosomal dominant polycystic kidney disease. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Thyroid disorders.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Autosomal dominant polycystic kidney disease
- Familial multinodular goiter syndrome
- Multinodular goiter
- Multinodular goiter, cystic kidney, polydactyly syndrome
- Non-toxic multinodular goiter
- Non-toxic nodular goiter
- Simple goiter
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Cystic goiter NOS
- Multinodular (cystic) goiter NOS
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Goiter (plunging) (substernal) - E04.9
- cystic - E04.2
- multinodular (cystic) (nontoxic) - E04.2
- multinodular - E04.2
- Struma - See Also: Goiter;
- multinodular - E04.2
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Goiter(plunging) (substernal)
- cystic
- Goiter(plunging) (substernal)
- multinodular (cystic) (nontoxic)
- Goiter(plunging) (substernal)
- nontoxic
- multinodular
- Struma
- nodosa (simplex)
- multinodular
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Multinodular Goiter
nodular goiter characterized by more than one discrete tissue mass.Non-Toxic Multinodular Goiter|Nontoxic multinodular goiter
a multinodular goiter that is not associated with changes in thyroid function or malignancy.Thyrotoxicosis with Toxic Multinodular Goiter with Thyrotoxic Crisis|Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis
evidence of thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis.Thyrotoxicosis with Toxic Multinodular Goiter without Thyrotoxic Crisis|Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis
evidence of thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis.Autosomal Dominant Polycystic Kidney Disease
polycystic kidney disease inherited in an autosomal dominant pattern. symptoms usually appear at middle age and include abdominal pain, hematuria and high blood pressure. patients may develop brain aneurysms and liver cysts.Autosomal Dominant Polycystic Kidney Disease Type 2
autosomal dominant polycystic kidney disease caused by a mutation in pkd2.Autosomal Dominant Polycystic Kidney Disease Type I
autosomal dominant polycystic kidney disease caused by a mutation in pkd1.Polycystic Kidney Disease, Infantile Severe, with Tuberous Sclerosis|Autosomal Dominant Polycystic Kidney Disease Type 1 with Tuberous Sclerosis|PKDTS|TSC2-PKD1 Contiguous Gene Deletion Syndrome
an autosomal dominant condition caused by a contiguous gene deletion involving the pkd1 and tsc2 genes, encoding polycystin-1 and tuberin respectively. it is characterized by polycystic kidneys and tuberous sclerosis.Polycystin-1|Autosomal Dominant Polycystic Kidney Disease Protein 1
polycystin-1 (4303 aa, ~463 kda) is encoded by the human pkd1 gene. this protein may play a role in protein-protein and protein-carbohydrate interactions during kidney development.Polycystin-1 Measurement|Autosomal Dominant Polycystic Kidney Disease 1 Protein|PC1|PKD1 Measurement|Polycystin 1, Transient Receptor Potential Channel Interacting|Polycystin-1|Polycystin-1|TRPP1
the determination of the polycystin-1 present in a sample.Polycystin-1|Autosomal Dominant Polycystic Kidney Disease Protein 1|PC1|Polycystic Kidney Disease-Associated Protein|Polycystin 1
polycystin-1 (4303 aa, ~463 kda) is encoded by the human pkd1 gene. this protein may play a role in protein-protein and protein-carbohydrate interactions during kidney development.
Patient EducationClinical
Thyroid Diseases
Your thyroid is a small, butterfly-shaped gland in the front of your neck. It makes hormones that control the way the body uses energy. These hormones affect nearly every organ in your body and control many of your body's most important functions. For example, they affect your breathing, heart rate, weight, digestion, and moods.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E04.2 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E04.2Overview
Is E04.2 (Other nontoxic goiter) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report nontoxic multinodular goiter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does E04.2 group to?
When nontoxic multinodular goiter is the principal diagnosis on an inpatient stay, it groups to MS-DRG 643, 644, 645, with relative weights from 0.7683 to 1.6461 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of E04.2?
Under the General Equivalence Mappings, nontoxic multinodular goiter converts to ICD-9-CM 241.1 (nontox multinodul goiter). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
